Top

Published in:

01-06-2011

Does Blood Pressure Variability Modulate Cardiovascular Risk?

Author: Peter M. Rothwell

Published in: Current Hypertension Reports | Issue 3/2011

Abstract

Exactly how hypertension causes end organ damage and vascular events is poorly understood. Yet the concept that underlying “usual” blood pressure (BP) accounts for all BP-related risk of vascular events and for the benefits of BP-lowering drugs has come to underpin clinical guidelines on the diagnosis and treatment of hypertension. This article reviews evidence that variability in BP also predicts risk of stroke and other vascular events independently of mean BP and evidence that drug-class effects on variability in BP explain differences in the effectiveness of BP-lowering drugs in preventing stroke.

Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697–716.PubMedCrossRef

Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87.PubMedCrossRef

Beckett LA, Rosner B, Roche AF, Guo S. Serial changes in blood pressure from adolescence into adulthood. Am J Epidemiol. 1992;135:1166–77.PubMed

Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305–15.PubMedCrossRef

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi:10.1136/bmj.b1665.PubMedCrossRef

Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895–905.PubMedCrossRef

Rothwell PM, Howard SC, Dolan E. et al; on behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469–80.PubMedCrossRef

Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375:906–15.PubMedCrossRef

Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375:938–48.PubMedCrossRef

10.

Sokolow M, Werdegar D, Kain HK, Hinman AT. Relationship between level of BP measured casually and by portable recorders and severity of complications in essential hypertension. Circulation. 1966;34:279–98.PubMed

11.

Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour BP variability. J Hypertens. 1993;11:1133–37.PubMedCrossRef

12.

Pessina AC, Palatini P, Sperti G, et al. Cordone. Evaluation of hypertension and related target organ damage by average day-time BP. Clin Exp Hypertens. 1985;A7:267–78.CrossRef

13.

Veerman DP, de Blok K, Delemarre BJ, van Montfrans GA. Office, nurse, basal and ambulatory BP as predictors of hypertensive target organ damage in male and female patients. J Hum Hypertens. 1996;10:9–15.PubMed

14.

Veerman DP, de Blok K, van Montfrans A. Relationship of steady state and ambulatory BP variability to left ventricular mass and urinary albumin excretion in essential hypertension. Am J Hypertens. 1996;9:455–60.PubMedCrossRef

15.

Mancia G, Parati G, Hennig M, et al. ELSA Investigators. Relation between BP variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 2001;19:1981–89.PubMedCrossRef

16.

Sega R, Corrao G, Bombelli M, et al. BP variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension. 2002;39:710–14.PubMedCrossRef

17.

Tatasciore A, Renda G, Zimarino M, et al. Awake systolic BP variability correlates with target-organ damage in hypertensive subjects. Hypertension. 2007;50:325–32.PubMedCrossRef

18.

Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Relation of BP variability to carotid atherosclerosis and carotid artery and left ventricular hypertrophy. Atheroscler Thromb Vasc Biol. 2001;21:1507–11.CrossRef

19.

Tohgi H, Chiba K, Kimura M. Twenty-four-hour variation of BP in vascular dementia of the Binswanger type. Stroke. 1991;22:603–8.PubMed

20.

Mart-Fabregas J, Valencia C, Pujol J, et al. BP variability and leukoaraiosis amount in cerebral small-vessel disease. Acta Neurol Scand. 2001;104:358–63.CrossRef

21.

Shimada K, Kawamoto A, Matsubayashi K, Ozawa T. Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure. Hypertension. 1990;16:692–9.PubMed

22.

Goldstein IB, Bartzokis G, Hance DB, Shapiro D. Relationship between BP and subcortical lesions in healthy elderly people. Stroke. 1998;29:765–72.PubMed

23.

Skoog I. A review on BP and ischaemic white matter lesions. Dement Geriatr Cogn Disord 1989(suppl 1): 13–19.

24.

Puisieux F, Monaca P, Deplanque D, et al. Relationship between leuko-araiosis and BP variability in the elderly. Eur Neurol. 2001;46:115–20.PubMedCrossRef

25.

Goldstein IB, Bartzokis G, Guthrie D, Shapiro D. Ambulatory BP and brain atrophy in the healthy elderly. Neurology. 2002;59:713–19.PubMed

26.

Goldstein IB, Bartzokis G, Guthrie D, Shapiro D. Ambulatory BP and the brain: a 5-year follow-up. Neurology. 2005;64:1846–52.PubMedCrossRef

27.

Kanemaru A, Kanemaru K, Kuwajima I. The effects of short-term BP variability and nighttime BP levels on cognitive function. Hypertens Res. 2001;24:19–24.PubMedCrossRef

28.

Kawamoto A, Shimada K, Matsubayashi K, et al. Factors associated with silent multiple lacunar lesions on magnetic resonance imaging in asymptomatic elderly hypertensive patients. Clin Exp Pharmacol Physiol. 1991;18:605–10.PubMedCrossRef

29.

Sierra C, de La Sierra A, Mercader J, et al. Silent cerebral white matter lesions in middle-aged essential hypertensive patients. J Hypertens. 2002;20:519–24.PubMedCrossRef

30.

Pickering TG, James GD. Ambulatory BP and prognosis. J Hypertens. 1994;12 suppl 8:S29–33.

31.

James GD, Pickering TG, Laragh JH. Ambulatory BP variation is related to plasma renin activity in borderline hypertensive men. Am J Hypertens. 1991;4:525–28.PubMed

32.

Kikuya M, Hozawa A, Ohokubo T, et al. Prognostic significance of BP and heart rate variabilities: the Ohasama study. Hypertension. 2000;36:901–6.PubMed

33.

Pringle E, Phillips C, Thijs L, et al. Syst-Eur investigators. Systolic BP variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens. 2003;21:2251–7.PubMedCrossRef

34.

Jokiniitty JM, Majahalme SK, Kahonen MA, Tuomisto MT, Turjanmaa VM. Prediction of blood pressure level and need for antihypertensive medication: 10 years of follow-up. J Hypertens. 2001;19:1193–201.PubMedCrossRef

35.

Sander D, Kukla C, Klingelhoffer J, Winbeck K, Conrad B. Relationship between circadian BP patterns and progression of early carotid atherosclerosis: A 3-year follow-up study. Circulation. 2000;102:1536–41.PubMed

36.

Eto M, Toba K, Akishita M, et al. Impact of BP variability on cardiovascular events in elderly patients with hypertension. Hypertens Res. 2005;28:1–7.PubMedCrossRef

37.

Verdecchia P et al. Prognostic significance of BP variability in essential hypertension: univariate and multivariate assessment. BP Monitoring. 1996;1:3–11.

38.

Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368–74.PubMedCrossRef

39.

Hansen TW, Thijs L, Li Y, et al. International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension. 2010;55:1049–57.PubMedCrossRef

40.

Veerabhadrappa P, Diaz KM, Feairheller DL, et al. Enhanced blood pressure variability in a high cardiovascular risk group of African Americans: FIT4Life Study. J Am Soc Hypertens. 2010;4:187–95.PubMedCrossRef

41.

Ko Y, Park JH, Yang MH, et al. The significance of blood pressure variability for the development of hemorrhagic transformation in acute ischemic stroke. Stroke. 2010;41:2512–8.PubMedCrossRef

42.

Armitage P, Fox W, Rose GA, Tinker CM. The variability of measurement of casual BP: ii Survey experience. Clin Sci. 1966;30:337–44.PubMed

43.

Rosner B, Polk BF. The implications of BP variability for clinical and screening purposes. J Chron Dis. 1979;32:451–61.PubMedCrossRef

44.

Hebel JR, Apostolides AY, Dischinger P, Entwistle G, Su S. Within-person variability in diastolic BP for a cohort of normotensives. J Chronic Dis. 1980;33:745–50.PubMedCrossRef

45.

Shepard DS. Reliability of BP measurements: implications for designing and evaluating programs to control hypertension. J Chronic Dis. 1981;34:191–209.PubMedCrossRef

46.

Rosner B, Polk BF. Predictive values of routine BP measurements in screening for hypertension. Am J Epidemiol. 1983;117:429–42.PubMed

47.

Rosner B, Polk BF. The implications of BP variability for clinical and screening purposes. J Chron Dis. 1979;32:451–61.PubMedCrossRef

48.

Cook NR, Rosner BA. Screening rules for determining BP status in clinical trials. Application to the trials of hypertension prevention. Am J Epidemiol. 1993;137:1341–52.PubMed

49.

Markovic N, Olomu IN, Bunker CH, et al. Adequacy of a single visit for classification of hypertensive status in a Nigerian civil servant population. Int J Epidemiol. 1994;23:723–9.PubMedCrossRef

50.

Klungel OH, de Boer A, Paes AHP, et al. Estimating the prevalence of hypertension corrected for the effect of within-person variability in BP. J Clin Epidemiol. 2000;53:1158–63.PubMedCrossRef

51.

Klungel OH, de Boer A, Paes AH, et al. Influence of correction for within-person variability in BP on the prevalence, awareness, treatment, and control of hypertension. Am J Hypertens. 2000;13:88–91.PubMedCrossRef

52.

Wittes J, Lakatos E, Black D, et al. Selecting screening criteria for clinical trials: an example from the Systolic Hypertension in the Elderly Program. Control Clin Trials. 1999;20:121–32.PubMedCrossRef

53.

Alli C, Mariotti G, Avanzini F, et al. Long-term prognostic impact of repeated measurements over 1 year of pulse pressure and systolic BP in the elderly. J Hum Hypertens. 2005;19:355–63.PubMedCrossRef

54.

Imai Y, Ohkubo T, Tsuji I, et al. Relationships among BPs obtained using different measurement methods in the general population of Ohasama, Japan. Hypertens Res. 1999;22:261–72.PubMedCrossRef

55.

Mancia G, Parati G, Bilo G, et al. Assessment of long-term antihypertensive treatment by clinic and ambulatory BP: data from the European Lacidipine Study on Atherosclerosis. J Hypertens. 2007;25:1087–94.PubMedCrossRef

56.

Wizner B, Dechering DG, Thijs L, et al. Short-term and long-term repeatability of the morning BP in older patients with isolated systolic hypertension. J Hypertens. 2008;26:1328–35.PubMedCrossRef

57.

Brueren MM, van Limpt P, Schouten HJ, et al. Is a series of BP measurements by the general practitioner or the patient a reliable alternative to ambulatory BP measurement? A study in general practice with reference to short-term and long-term between-visit variability. Am J Hypertens. 1997;10:879–85.PubMedCrossRef

58.

Hata Y, Kimura Y, Muratani H, et al. Office BP variability as a predictor of brain infarction in elderly hypertensive patients. Hypertens Res. 2000;23:553–60.PubMedCrossRef

59.

Hata Y, Muratani H, Kimura Y, et al. Office BP variability as a predictor of acute myocardial infarction in elderly patients receiving antihypertensive therapy. J Hum Hypertens. 2002;16:141–6.PubMedCrossRef

60.

Tozawa M, Iseki K, Yoshi S, Fukiyama K. BP variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant. 1999;14:1976–81.PubMedCrossRef

61.

Havlik RJ, Foley DJ, Sayer B, et al. Variability in midlife systolic BP is related to late-life brain white matter lesions: the Honolulu-Asia Aging study. Stroke. 2002;33:26–30.PubMedCrossRef

62.

Wingfield D, Grodzicki T, Palmer AJ, Wells F, Bulpitt CJ, on behalf of the General Practice Hypertension Study Group. Transiently elevated diastolic BP is associated with a gender-dependent effect on cardiovascular risk. J Hum Hypertens. 2005;19:347–54.PubMedCrossRef

63.

Kikuya M, Ohkubo T, Metoki H, et al. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension. 2008;52:1045–50.PubMedCrossRef

64.

Muntner P, Shimbo D, Tonelli M, et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension. 2011;57:160–6.PubMedCrossRef

65.

Kilpatrick ES, Rigby AS, Atkin SL. The role of blood pressure variability in the development of nephropathy in type 1 diabetes. Diabetes Care. 2010;33:2442–7.PubMedCrossRef

66.

Geeganage C, Tracy M, England T, et al. TAIST Investigators. Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure, and variability) and early outcome after stroke: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). Stroke. 2011;42:491–3.PubMedCrossRef

67.

Wizner B, Dechering DG, Thijs L, et al. Short-term and long-term repeatability of the morning BP in older patients with isolated systolic hypertension. J Hypertens. 2008;26:1328–35.PubMedCrossRef

68.

Kario K, Shimada K, Pickering TG. Clinical implication of morning BP surge in hypertension. J Cardiovasc Pharmacol. 2003;42 Suppl 1:S87–91.PubMedCrossRef

69.

Koton S, Tanne D, Bornstein NM, Green MS. Triggering risk factors for ischemic stroke: a case-crossover study. Neurology. 2004;63:2006–10.PubMed

70.

Brotman DJ, Golden SH, Wittstein IS. The cardiovascular toll of stress. Lancet. 2007;370:1089–100.PubMedCrossRef

71.

Kazuomi K. Orthostatic hypertension: a measure of blood pressure variation for predicting cardiovascular risk. Circ J. 2009;73:1002–7.CrossRef

72.

Fessel J, Robertson D. Orthostatic hypertension: when pressor reflexes overcompensate. Nat Clin Pract Nephrol. 2006;2:424–31.PubMedCrossRef

73.

Pavek K, Taube A. Personality characteristics influencing determinacy of day and night blood pressure and heart rate. Blood Press. 2009;18:30–5.PubMedCrossRef

74.

Brondolo E, Grantham KI, Karlin W, et al. Trait hostility and ambulatory blood pressure among traffic enforcement agents: the effects of stressful social interactions. J Occup Health Psychol. 2009;14:110–21.PubMedCrossRef

75.

Federowski A, Stavenow L, Hedblad B, et al. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Prevention Project). Eur Heart J. 2010;31:85–91.CrossRef

76.

Hossain M, Ooi WL, Lipsitz LA. Intra-individual postural blood pressure variability and stroke in elderly nursing home residents. J Clin Epidemiol. 2001;54:488–94.PubMedCrossRef

77.

Kamaruzzaman S, Watt H, Carson C, Ebrahim S. The association between orthostatic hypotension and medication use in the British Women's Heart and Health Study. Age Ageing. 2010;39:51–6.PubMedCrossRef

78.

Verdecchia P, O'Brien E, Pickering T, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. When can the practicing physician suspect white coat hypertension? Statement from the Working Group on Blood Pressure Monitoring of the European Society of Hypertension. Am J Hypertens. 2003;16:87–91.PubMedCrossRef

79.

Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47:846–53.PubMedCrossRef

80.

Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226–32.PubMedCrossRef

81.

Pickering TG, Eguchi K, Kario K. Masked hypertension: a review. Hypertens Res. 2007;30:479–88.PubMedCrossRef

82.

Heuschmann PU, Grieve AP, Toschke AM, Rudd AG, Wolfe CD. Ethnic group disparities in 10-year trends in stroke incidence and vascular risk factors: the South London Stroke Register (SLSR). Stroke. 2008;39:2204–10.PubMedCrossRef

83.

Duprez DA, Jacobs Jr DR, Lutsey PL, et al. Race/ethnic and sex differences in large and small artery elasticity–results of the multi-ethnic study of atherosclerosis (MESA). Ethn Dis. 2009;19:243–50.PubMed

84.

Tozawa M, Iseki K, Yoshi S, Fukiyama K. Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant. 1999;14:1976–81.PubMedCrossRef

85.

Fischer U, Bull L, Silver LE, Mehta Z, Rothwell PM. Acute phase blood pressure after TIA and stroke in relation to pre-morbid levels: a population based study. Cerebrovasc Dis. 2009;27 suppl 6:60 (Abstract).

86.

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcome in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97.CrossRef

87.

MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405–12.CrossRef

88.

Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed). 1985;291:97–104.CrossRef

89.

Angeli F, Verdicchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens. 2004;17:817–22.PubMed

90.

Webb AJS, Rothwell PM. Blood pressure variability and risk of new-onset atrial fibrillation: a systematic review of randomized trials of antihypertensive drugs. Stroke. 2010;41:2091–3.PubMedCrossRef

91.

Web AJS, Fischer U, Rothwell PM. Detrimental effects of non-selective beta-blockers on blood pressure variability and risk of stroke: A systematic review. Neurology 2011 (in press).

92.

Miao CY, Xie HH, Zhan LS, Su DF. BP variability is more important than BP level in determination of end-organ damage in rats. J Hypertens. 2006;24:1125–35.PubMedCrossRef

93.

Shan ZZ, Dai SM, Su DF. Arterial baroreflex deficit induced organ damage in sinoaortic denervated rats. J Cardiovasc Pharmacol. 2001;38:427–37.PubMedCrossRef

94.

Su DF. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies. Curr Opin Cardiol. 2006;21:486–91.PubMedCrossRef

95.

Tatasciore A, Zimarino M, Renda G, et al. Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. Hypertens Res. 2008;31:2137–46.PubMedCrossRef

96.

Desjardins F, Sekkali B, Verreth W, et al. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Eur Heart J. 2008;29:128–37.PubMedCrossRef

97.

Sorond FA, Khavari R, Serrador JM, Lipsitz LA. Regional cerebral autoregulation during orthostatic stress: age-related differences. J Gerontol A Biol Sci Med Sci. 2005;60:1484–7.PubMed

98.

Zhang R, Witkowski S, Fu Q, Claassen JA, Levine BD. Cerebral hemodynamics after short- and long-term reduction in blood pressure in mild and moderate hypertension. Hypertension. 2007;49:1149–55.PubMedCrossRef

99.

Rothwell PM, Howard SC, Spence D. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke. 2003;34:2583–90.PubMedCrossRef

100.

Lammie GA, Lindley R, Keir S, Wiggam MI. Stress-related primary intracerebral hemorrhage: autopsy clues to underlying mechanism. Stroke. 2000;31:1426–8.PubMed

101.

Moody DM, Brown WR, Challa VR, Ghazi-Birry HS, Reboussin DM. Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer's disease. Ann NY Acad Sci. 1997;826:103–16.PubMedCrossRef

102.

Meyer JS, Waltz AG, Gotoh F. Pathogenesis of cerebral vasospasm in hypertensive encephalopathy. I. Effects of acute increases in intraluminal blood pressure on pial blood flow. Neurology. 1960;10:735–44.

103.

Thom S, Stettler C, Stanton A, et al. Differential effects of antihypertensive treatment on the retinal microcirculation: an Anglo-Scandinavian Cardiac Outcomes Trial substudy. Hypertension. 2009;54:405–8.PubMedCrossRef

Title: Does Blood Pressure Variability Modulate Cardiovascular Risk?
Author: Peter M. Rothwell
Publication date: 01-06-2011
Publisher: Current Science Inc.
Published in: Current Hypertension Reports / Issue 3/2011
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-011-0201-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Stress and Its Role in Sympathetic Nervous System Activation in Hypertension and the Metabolic Syndrome

Alcohol Consumption, Blood Pressure, and the Risk of Stroke

New Approaches to Quantifying Sympathetic Nerve Activity

Mineralocorticoid Actions in the Brain and Hypertension

Diabetic Retinopathy and Blockade of the Renin-Angiotensin System: So What is New?

Vascular Mechanisms in the Pathogenesis of Stroke

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials